Privacy preferences
Inderes uses cookies to provide a better user experience and a personalised service. By consenting to the use of cookies, we can develop an even better service and will be able to provide content that is interesting to you.
  • Forum
  • Premium
  • Stock Markets
    • MarketsLive prices, indices, and market performance
    • Morning ReviewDaily market recap and key overnight highlights
    • Stock CalendarUpcoming earnings, listings, and corporate events
    • Dividends CalendarFuture and past dividends
  • Companies
    • CompaniesBrowse and filter the full list of listed companies
    • DiscoveryInspiration for your next investment
    • IPOsNew listings and upcoming public offerings
    • AGM InvitationsAnnual general meeting dates and shareholder info
  • Stock Research
    • ResearchExpert stock analysis and recommendations
    • ArticlesNews, insights, and market commentary
    • PortfolioInderes model portfolio
    • FemmeBreaking barriers and building confidence in investing
  • Learn about investing
    • Analysis SchoolLearn how to read and understand stock analysis
    • Investing SchoolGuides and lessons to grow your investing knowledge
    • Portfolio buildersInvesting knowledge for every level, from first steps to advanced portfolio strategies.
    • inderesTVVideo hub for stock research, analysis, and expert commentary
    • TranscriptsFull text records of earnings calls and investor meetings
    • Stock ComparisonCompare financials and performance across multiple stocks
    • Earnings SeasonCompare EPS estimates to reported results
    • Insider TransactionsTrack buying and selling activity by company insiders
    • Short SellingSee which listed companies have disclosed short interest
    • Virtual Analyst ChatAsk questions and get instant AI-powered investment insights
    • Compound Interest CalculatorSee how your savings grow with the power of compound interest.
Find us on social media
  • Inderes Forum
  • Youtube
  • Facebook
  • Instagram
  • X (Twitter)
  • Tiktok
  • Linkedin
Get in touch
  • info@inderes.fi
  • +358 10 219 4690
  • Porkkalankatu 5
    00180 Helsinki
Inderes
  • About us
  • Our team
  • Careers
  • Inderes as an investment
  • Services for listed companies
Our platform
  • FAQ
  • Q&A
  • Terms of service
  • Privacy policy
  • Disclaimer

Inderes’ Disclaimer can be found here. Detailed information about each share actively monitored by Inderes is available on the company-specific pages on Inderes’ website. © Inderes Oyj. All rights reserved.

CLS and advanced fiber tools enter strategic partnership to pursue broader commercial opportunities in medical laser therapy

CLS BRegulatory press release19.11.2026 klo 09.30
Download the release

Lund, Sweden, [date] - Clinical Laserthermia Systems AB (publ) ("CLS") today announces that it has entered into a strategic partnership agreement with advanced fiber tools GmbH ("AFT") to jointly pursue new commercial opportunities by combining CLS's proprietary non-cooled laser technology with AFT's expertise in fiber-optic engineering and manufacturing.

 

Building on their established manufacturing collaboration, the companies aim to identify and develop specialized medical laser products for therapeutic uses across a broad range of markets beyond CLS's existing partnerships in neurosurgery and urology. CLS believes the combined commercial potential of these additional markets could exceed that of its currently targeted markets, creating opportunities for long-term growth and diversification.

 

"This agreement is an important step in unlocking the broader commercial potential of our technology. While our current business is focused primarily on neurosurgery, we believe there are significant opportunities across additional therapeutic areas that remain largely untapped by CLS. Together with AFT, we aim to pursue these opportunities through a resource-efficient, partnership-led approach," says Dan Johansson Mogren, CEO of CLS.

 

"Our long-standing collaboration with CLS provides a strong foundation for further innovation. By combining our complementary technologies and expertise, we see opportunities to develop differentiated products addressing new therapeutic needs," says Naim Ashraf, CSO of advanced fiber tools GmbH.

 

The agreement establishes a non-exclusive framework for evaluating and pursuing opportunities, with individual development and commercialization projects to be agreed separately. It does not involve immediate financial commitments or guaranteed commercial volumes and does not affect the companies' existing Manufacturing Agreement.

 

 

About advanced fiber tools GmbH

advanced fiber tools GmbH is a German company specializing in the development and manufacturing of advanced fiber-optic products and customized solutions for medical and other specialized applications. For more information about AFT, please visit the Company's website: advanced fiber tools GmbH

 

For more information, please contact:

Dan J. Mogren, CEO, Clinical Laserthermia Systems AB (publ)

Phone: +46 (0) 70-590 11 40

E-post: dan.mogren@clinicallaser.com

 

 

 

About CLS

Clinical Laserthermia Systems AB (publ), develops and sells TRANBERG® Thermal Therapy System and ClearPoint Prism® Neuro Laser Therapy System with sterile disposables, for minimally invasive treatment of cancer tumors and drug-resistant epilepsy. The products are marketed and sold through partners for image-guided laser ablation. CLS is headquartered in Lund, Sweden, with subsidiaries in Germany, the United States and a marketing company in Singapore. CLS is listed on Nasdaq First North Growth Market under the symbol CLS B. Certified adviser (CA) is FNCA Sweden AB.

 

For more information about CLS, please visit the Company's website: www.clinicallaser.se

This disclosure contains information that CLS is obliged to make public pursuant to the EU Market Abuse Regulation (EU nr 596/2014). The information was submitted for publication, through the agency of the contact person, on 19-11-2026 08:30 CET.